Adequate reimbursement for molecular diagnostic tests can improve patient care

NewsGuard 100/100 Score

The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the results of its qualitative and quantitative "Analysis of Professional Work Effort in Molecular Test Interpretation Report."

More than 100 molecular professionals from the AMP and American College of Medical Genetics and Genomics (ACMG) communities reported that their efforts spent on data analysis, interpretation, and reporting for molecular diagnostic tests were not sufficiently reimbursed.

Respondents indicated that adequate reimbursement for these activities would improve patient care by increasing access to these essential medical services and enabling more data-driven treatment decisions.

Molecular diagnostic services are currently provided by both physicians and qualified doctoral scientists with specialized training and experience. The survey found that the extensive analysis, interpretation, and reporting requirements can often take more than six hours per test. However, that time, expertise, and professional effort are not adequately accounted for or reimbursed under existing payment systems.

As molecular diagnostic procedures become increasingly complex, and both the value and need for testing continue to grow, so does demand for the services of qualified molecular laboratory professionals. The vital services these professionals provide need to be accounted for and reimbursed. AMP looks forward to working with all interested stakeholders to help ensure fair and reasonable reimbursement that provides more patients with better access to these valuable test procedures."

Samuel K. Caughron MD, Chair and President, Economic Affairs Committee, The Association for Molecular Pathology

Caughron is also the CEO of MAWD Pathology Group. Since 2011, AMP has been a leading advocate for appropriate reimbursement for qualified healthcare professionals who are providing high-quality molecular diagnostic services. The results of this assessment will be crucial in providing data to inform discussions with payers, federal agencies, and members of Congress.

AMP will continue to actively work with many professional organizations as part of its ongoing commitment to informing and influencing public policies that ensure fair and reasonable reimbursement solutions.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes